Mather Group’s Protagonist Therapeutics PTGX Stock Holding History

Mather Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.09K	Buy	+29	New	+$4.13K	﹤0.01%	1854

Other funds holding PTGX

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Mather Group's PTGX Position: Q3 2026 in Review

Mather Group opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 29 shares worth $4.09K. The stake represents ﹤0.01% of the portfolio and ranks #1854 among its holdings.

56 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

Mather Group held 29 shares of Protagonist Therapeutics worth $4.09K as of Q3 2026.
Protagonist Therapeutics was a new Mather Group position in Q3 2026.
Protagonist Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1854 holding.
56 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.